{"id":457511,"date":"2021-03-15T08:33:11","date_gmt":"2021-03-15T12:33:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457511"},"modified":"2021-03-15T08:33:11","modified_gmt":"2021-03-15T12:33:11","slug":"sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/","title":{"rendered":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <em>&#8212; Ten abstracts, including four podium presentations, reflect Sarepta\u2019s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions &#8212;<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">CAMBRIDGE, Mass., March  15, 2021  (GLOBE NEWSWIRE) &#8212; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:7.2pt;margin-bottom:7.2pt;text-align:justify\">New, two- and one-year data including expression data from muscle biopsies taken two years post-treatment, from Study 9003-101 of SRP-9003, an investigational gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2E\/R4;<\/li>\n<li style=\"margin-top:7.2pt;margin-bottom:7.2pt;text-align:justify\">Data from Part 1 of Study 9001-102, an ongoing clinical trial of SRP-9001, Sarepta\u2019s investigational gene therapy for Duchenne muscular dystrophy and pre-clinical approaches to the challenge of pre-existing antibodies; and,<\/li>\n<li style=\"margin-top:7.2pt;margin-bottom:7.2pt;text-align:justify\">An analysis of time to loss of ambulation in patients taking eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne, compared to standard of care.<\/li>\n<\/ul>\n<p align=\"justify\">All posters are available on-demand throughout the Congress beginning on Monday, March 15, 2021 at 6:00 a.m. ET. Podium presentations will take place on Thursday, March 18, 2021. The full MDA 2021 Virtual Congress program is available here:\u00a0 <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wO75e8RAcHBqp4jTPoOJnQbmLPj_4rFHAxBcmsm1PuQQRF79ElOMaRbVI_8tL1zbYyWiCq1PkzrggtvwnIzzZpBeciMhsm6NqKyfkq8LOhKqZ7dE8zXS2DHT2OoEAENEcANqeE7SqnpynOjGkqNIVq_jBgM-pyeLGlCMWvmql-rgvZ2FKLk0Q-jcYkxrXrWu5uiuN22Nyb5xCMWh7GkbjJVvVy4skW1gI5hjUADArQhxYZSCouvRZo_E0l4-yYCYSIaK8q66frwnlxkW4JgAVL-vEece3azpvGCB9WJ4R-44t1gHmwRj-x1LI0LxuOTkYet_7Fp2cEFtmvUTrPaeU6nu0I34elYNNzw0dKDVpg_WMjyaCnmO2y9j9nOrymTcc1TCNHlSIU4WAxW5H6nGHgAKxAC1giySVJM8PJ8HPC_baIolPUh0cLtCEbxHQb4huZnIr0TfyNZ4elJ-lXLuFmtVaUSnaBmlAbwVOlSvaDwg7mmgeVY8pAqDB0P9RSwfMKciT7PANyG6W7clnqwClWHO0gNOV2cCuH14ev6sYCyP3XQhT7BXzXf6WBsp-_kEarxLrlKzWtTMz3UfBHIfQqFgFkl4M7KxB3miLhUF9GAhNzpy_OFIKK9bboMya10YQFXRtXDucMF_HwveVdGAcnKmUqvfMBhoTj-42AhB0TO8d_yGIEFa6qtxCF0DMZ6lNC8EY-P0is1Xde2ssJhFfTL1YocnReWsRm3F6UQVGvD8GgTvcfuzEvjlQOYcCZDzvgVcwEUFXTSx6EqRkROPBw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/mdaconference.org<\/a><\/u>.<\/p>\n<p align=\"justify\">\n        <strong> Podium Presentations:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:75%;width:75%;min-width:75%;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Title <\/strong>\n          <\/td>\n<td style=\"max-width:10%;width:10%;min-width:10%;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Program<\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;vertical-align: top\">\n            <strong>Date, Time<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Micro-dystrophin Gene Therapy Delivery and Therapeutic Plasma Exchange in Non-Human Primates\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">SRP-9001<\/p>\n<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;vertical-align: top\">Thurs., March 18, 2021 <br \/>10:30-10:45 AM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">SRP-9001<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;vertical-align: top\">Thurs., March 18, 2021 <br \/>3:30-3:45 PM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Safety,\u00a0\u03b2-sarcoglycan\u00a0Expression, and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.SGCB in Limb\u00a0Girdle Muscular Dystrophy Type 2E\/R4<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">SRP-9003<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;vertical-align: top\">Thurs., March 18, 2021 <br \/>4:30-4:45 PM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Delay in Duchenne Muscular Dystrophy Progression with Eteplirsen: Longer Time to Loss of Ambulation Versus Standard of Care<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">Eteplirsen<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;vertical-align: top\">Thurs., March 18, 2021 <br \/>5:45-6:00 PM ET<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>Poster Presentations: <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong> Poster #<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <strong>Title<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">6<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Biological Efficacy of the Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer SRP-5051 in Preclinical Models of Duchenne Muscular Dystrophy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">54<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Casimersen Treatment in Eligible Patients with Duchenne Muscular Dystrophy: Safety, Tolerability, and Pharmacokinetics Over 144 Weeks of Treatment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">90<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Patterns of Clinical Progression Among Patients with Autosomal Recessive Limb-Girdle Muscular Dystrophy (LGMDR): A Systematic Review<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">92<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Progression to Loss of Ambulation (LOA) Among Patients with Autosomal Recessive Limb-Girdle Muscular Dystrophy (LGMDR): A Systematic Review<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">104<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Health-related quality of life (HRQoL) Associated with Duchenne Muscular Dystrophy (DMD): A Study Using the Health Utilities Index Mark 3 (HUI3)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">113<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">NorthStar Ambulatory Assessment (NSAA) and Health Utilities Index (HUI) Scores are Weakly Correlated Among Boys with Duchenne Muscular Dystrophy (DMD)<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Presentations will be archived on the events and presentations page in the Investor Relations section of www.sarepta.com for one year following their presentation at MDA.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Sarepta Therapeutics<\/strong><br \/>\n        <br \/>At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company\u2019s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xAKbZfGNdU5vfvYxZ4HNFveHAqo7n3a9hLWFs6r2e68hB3xXbPvQss3qRMPsm61kp6IJ_QW3tQWKlVHakdM22g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sarepta.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pya5xYyprD_Mb04yzcCU-kFJg_4wGOt6BHbci9KbSEgNvv0jS-b4wwP-yr81bHvPyloljPv8eCUQMSBtA1896A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KUqfz6D7XRxFgJqkpO2XLRzrpuHTADTEiwnB1QYs28GXqAhZrGvLYMVGQkb3cpWA8tJ22wj6JPRtwSZmujoWlIP_Vi1ZgZL_NoZmHVmprPP-rk9TXNM4aC3KCn0jH3vz\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PHRsrK4J1REi3g1mZe6jeUrsHJ5L_1ILXwWYWsTUodq8pArg2OLJF41ro7Jh_-24HTzt1Z-7X0VppYvaBLwV5a7sGaCIg22YCtHt8NEz2Q8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Instagram<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e1VaStXZw626TqbH43TEqruPwHSelCo2oGUwiugg9_8jWJGl1vQ8dut6imgJ3hdzP2QE4jKhvcY_54WajG53Gal_IuT2NwRatcq1z-UKeI_so22QS0xfv0zA46kKU5mv\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Internet Posting of Information<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>We routinely post information that may be important to investors in the &#8216;For Investors&#8217; section of our website at\u00a0<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xAKbZfGNdU5vfvYxZ4HNFuC7H8cG9VV6QbYdfH0hBKx6gLEs7zIekU2aoMTJuOkdJBSbb-koM74Ys73jG-VTZg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <em><br \/>\n            <u>www.sarepta.com<\/u><br \/>\n          <\/em><br \/>\n        <\/a><br \/>\n        <em>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/em>\u00a0\u00a0<\/p>\n<p>Source: Sarepta Therapeutics, Inc.<\/p>\n<p>Sarepta Therapeutics, Inc.<\/p>\n<p>Investors:<br \/>Ian Estepan, 617-274-4052, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f42F6SwIOy1hJYYGMQ_gz9b8LRoncWbd0T_RHatjMQErQCSKTdsi_rhX2G2Btd3vYnyd7xBXzGpsqI8FlZ6SK8wcu1MMh4Y0u3iieX5WHWY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">iestepan@sarepta.com<\/a><\/p>\n<p>Media:<br \/>Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e566c232-6c96-4a64-9156-8b23e2aa4577\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Ten abstracts, including four podium presentations, reflect Sarepta\u2019s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions &#8212; CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented: New, two- and one-year data including expression data from muscle biopsies taken two years post-treatment, from Study 9003-101 of SRP-9003, an investigational gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2E\/R4; Data from Part 1 of Study 9001-102, an ongoing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457511","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Ten abstracts, including four podium presentations, reflect Sarepta\u2019s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions &#8212; CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented: New, two- and one-year data including expression data from muscle biopsies taken two years post-treatment, from Study 9003-101 of SRP-9003, an investigational gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2E\/R4; Data from Part 1 of Study 9001-102, an ongoing &hellip; Continue reading &quot;Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T12:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference\",\"datePublished\":\"2021-03-15T12:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/\"},\"wordCount\":628,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/\",\"name\":\"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\",\"datePublished\":\"2021-03-15T12:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk","og_description":"&#8212; Ten abstracts, including four podium presentations, reflect Sarepta\u2019s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions &#8212; CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented: New, two- and one-year data including expression data from muscle biopsies taken two years post-treatment, from Study 9003-101 of SRP-9003, an investigational gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2E\/R4; Data from Part 1 of Study 9001-102, an ongoing &hellip; Continue reading \"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T12:33:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference","datePublished":"2021-03-15T12:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/"},"wordCount":628,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/","name":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=","datePublished":"2021-03-15T12:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc5OCM0MDYyOTMxIzIwMDcxNTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-2021-annual-mda-clinical-and-scientific-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457511"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457511\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}